Molly Harper is the Chief Business Officer at Synlogic and is a member of the Board of Directors for Catalyst Pharmaceuticals and PreciseDx, bringing more than 20 years of operating experience in the biopharma industry, with a focus on translating development assets into commercialized products. She previously served as Executive Vice President of Operations for Relmada Therapeutics, and was a member of the founding team at Akcea Therapeutics, where her last position was Senior Vice President and Global Franchise General Manager, with responsibility for a six-drug portfolio, including the commercialization of two rare disease drugs. Ms. Harper previously served in commercial leadership positions at Genzyme and Merck & Co. She holds an MBA from The Wharton School at the University of Pennsylvania, and a BA from Cornell University.